NCT01960478 is a NA clinical trial of (for each intervention) in Cerebral Vascular Accident (CVA), sponsored by University Hospital, Strasbourg, France.

Who is sponsoring NCT01960478?

NCT01960478 is sponsored by University Hospital, Strasbourg, France.

What drugs are being tested in NCT01960478?

Interventions in NCT01960478: (for each intervention), Blood test.

What condition does NCT01960478 study?

NCT01960478 studies Cerebral Vascular Accident (CVA).

Is NCT01960478 still recruiting?

NCT01960478 is currently completed. Last updated 9 March 2021.

Last reviewed 2021-03-09 · How we verify

NCT01960478

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke

Completed NA Last updated 9 March 2021

What this trial tests

NA trial testing (for each intervention) in Cerebral Vascular Accident (CVA) in 150 participants. Completed in 5 October 2014.

Timeline

7 January 2014

Primary endpoint
5 October 2014

5 October 2014

Quick facts

Lead sponsor	University Hospital, Strasbourg, France
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	150
Start date	7 January 2014
Primary completion	5 October 2014
Estimated completion	5 October 2014
Sites	1 location across France

Drugs / interventions tested

(for each intervention) — full drug profile →
Blood test — full drug profile →

Conditions studied

Cerebral Vascular Accident (CVA) — all drugs for Cerebral Vascular Accident (CVA) →

Sponsor

University Hospital, Strasbourg, France

Who can join

18 and older, any sex, with Cerebral Vascular Accident (CVA). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the USA, every year 795,000 patients suffer a cerebral vascular accident (CVA), which represents a yearly cost of $73.7 billion. CVA is the third main cause of death and the main source of acquired handicap in adults, as a result it is now a key priority in public health and part of " The CVA National Action Plan 2013-2014". Copeptin is a polypeptide, by- product of Vasopressin metabolism. The increase of Copeptin plasma level, as for Vasopressin, is connected to hydric balance disorders found in cardio-vascular, renal and endocrine diseases. This link has already shown its interest in the early diagnosis of myocardial infarction and, in a more indirect way, CVA. Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimeres in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in development of biomarkers for brain damage and ischemia.
Karimova D, Rostami E, Chubarev VN, Tarasov VV, et al · · 2024 · cited 5× · PMID 39001884 · DOI 10.1007/s11033-024-09708-x

Verify or expand the search:

Other University Hospital, Strasbourg, France trials

Trials by the same sponsor.

NCT07418554 — Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Pla · Phase 3 · not yet recruiting
NCT07108582 — Reducing Chronic Pain After Lung Surgery: A Trial of Limiting NSAIDs During Recovery · Phase 3 · not yet recruiting
NCT07302646 — Optimizing Reduced-Flow, Low-Volume Contrast Protocols for Cerebral Angiography in Unruptured Aneurysms · NA · not yet recruiting
NCT07273968 — Clinical Study Evaluating the Effect of Virtual Reality on Reducing Patients' Anxiety During Wisdom Teeth Extraction · NA · not yet recruiting
NCT07214103 — Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulop · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01960478 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Strasbourg, France
Last refreshed: 9 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01960478.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing